Miller fisher anti-GQ1b antibodies: α-Latrotoxin - Like effects on motor end plates

Annals of Neurology

Volumn 45, Issue 2, 1999, Pages 189-199

  Plomp, Jaap J ^a   Molenaar, Peter C ^a   O'Hanlon, Graham M ^c   Jacobs, Bart C ^b   Veitch, Jean ^c   Daha, Mohamed R ^a   Van Doorn, Pieter A ^b   Van Der Meché, Frans G A ^b   Vincent, Angela ^d   Morgan, Bryan P ^e   Willison, Hugh J ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA LATROTOXIN; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GQ 1B; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; EXTRAOCULAR MUSCLE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN TISSUE; MALE; MINIATURE ENDPLATE POTENTIAL; MOUSE; MUSCLE WEAKNESS; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SERUM;

ANIMALS; ANTIBODIES; ELECTROPHYSIOLOGY; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MILLER FISHER SYNDROME; MOTOR ENDPLATE; SPIDER VENOMS;

EID: 0033040642     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T     Document Type: Article

References (46)

1. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;225:57-65
2. O'Leary CP, Veitch J, Durward WF, et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996;61:649-652
3. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-1917
4. Chiba A, Kusunoki S, Shimuzu T, Kanazawa I, Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller-Fisher syndrome. Ann Neurol 1992;31:677-679
5. Willison HJ, Veitch J, Paterson, Kennedy PGE, Miller-Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204-206
6. Yuki N, Sato S, Tsuiji S, et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993;43:414-417
7. Ledeen RW, Wu G. Ganglioside function in the neuron. Trends Glycosci Glycotech 1992;4:174-187
8. Jacobs BC, Endtz H, Van der Meche FG, et al. Serum anti-GQ1b antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995;37:260-264
9. Salloway S, Mermel LA, Seamans M, et al. Miller Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect Immun 1996;64:2945-2949
10. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ1b ganglioside and liposaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791-793
11. Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 1994;343:454-455
12. Buchwald B, Weishaupt A, Toyka K, Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci Lett 1995;201:163-166
13. Buchwald B, Weishaupt A, Toyka K, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998;10:281-290
14. Schwarz A, Futerman AH. The localization of gangliosides in neurons of the central nervous system: the use of antiganglioside antibodies. Biochim Biophys Acta 1996;1286:247-267
15. Notermans SHW, Wokke JHJ, Van den Berg LH. Botulism and Guillain-Barre syndrome. Lancet 1992;340:303 (Letter)
16. Rosenthal L, Meldolesi J. Alpha-latrotoxin and related toxins. Pharmacol Ther 1989;42:115-134
17. Willison HJ, O'Hanlon GM, Paterson G, et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J Clin Invest 1996;97:1155-1164
18. Willison HJ, Paterson G, Veitch J, et al. Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins. J Neurol Neurosurg Psychiatry 1993;56:1178-1184
19. Van den Berg RH, Faber-Krol M, Van Es LA, Daha MR. Regulation of the function of the first component of complement by human C1q receptor. Eur J Immunol 1995;25:2206-2210
20. Abraha A, Morgan BP, Luzio JP. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J 1988;251:285-292
21. Boelaert J, Joos R, Criel A, et al. C5 deficiency in a white family. Arch Intern Med 1985;145:1333 (Letter)
22. Cruz LJ, Gray WR, Olivera BM, et al. Conus geographus toxins that discriminate between neuronal and muscle sodium channels. J Biol Chem 1985;260:9280-9288
23. Di Gregorio F, Fesce R, Cereser S, et al. Spontaneous and nerve-evoked quantal transmission in regenerated motor terminals. Cell Biol Int Rep 1989;13:1119-1126
24. Hong SJ, Chang CC. Use of geographutoxin II (μ-conotoxin) for the study of neuromuscular transmission in the mouse. Br J Pharmacol 1989;97:934-940
25. Plomp JJ, Van Kempen GThH, Molenaar PC. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in α-bungarotoxin-treated rats. J Physiol (Lond) 1992;458:487-499
26. O'Hanlon GM, Paterson GJ, Wilson G, et al. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J Neuropathol Exp Neurol 1996;55:184-195
27. Angaut-Petit D, Juzans P, Molgo J, et al. Mouse motor nerve terminal immunoreactivity to synaptotagmin II during sustained quantal transmitter release. Brain Res 1995;681:213-217
28. Hong SJ, Chang CC. Inhibition of acetylcholine release from mouse motor nerve by a P-type calcium channel blocker, ω-agatoxin IVA. J Physiol (Lond) 1995;482:283-290
29. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994;50:159-165
30. Whaley K. An introduction to the complement system. In: Whaley K, ed. Methods in complement for clinical immunologists. New York: Churchill Livingstone, 1985:1-21
31. Jacobs BC, Endtz HP, Van der Meché FGA, et al. Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome. J Neuroimmunol 1997;79:62-68
32. Hurlbut WP, Iezzi N, Fesce R, Ceccarelli B. Correlation between quantal secretion and vesicle loss at the frog neuromuscular junction. J Physiol (Lond) 1990;425:501-526
33. Morgan BP. Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 1995;32:265-298
34. Turner MW. The lectin pathway of complement activation. Res Immunol 1996;147:110-115
35. Nicholson-Weller A, Halperin JA. Membrane signalling by complement C5b-9, the membrane attack complex. Immunol Res 1993;12:244-257
36. Van der Kloot W, Molgó J. Quantal acetylcholine release at the vertebrate neuromuscular junction. Physiol Rev 1994;74:899-991
37. Koski CL, Sanders ME, Swoveland PT, et al. Activation of terminal components of complement in patients with Guillain Barré syndrome and other demyelinating neuropathies. J Clin Invest 1987;80:1492-1497
38. Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV. Guillain-Barré syndrome: activated complement components C3a and C5a in CFS. Neurology 1987;37:1006-1009
39. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644
40. Hafer-Macko C, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-635
41. Valtorta F, Maddedu L, Meldolesi J, Ceccarelli B. Specific localization of the α-latrotoxin receptor in the nerve terminal plasma membrane. J Cell Biol 1984;99:124-132
42. Petrenko AG, Perin MS, Davletov BA, et al. Binding of synaptotagmin to the α-latrotoxin receptor implicates both in synaptic vesicle exocytosis. Nature 1991;353:65-68
43. Krasnoperov VG, Bittner MA, Beavis R, et al. α-Latrotoxin stimulates exocytosis by the interaction with a neuronal G-protein-coupled receptor. Neuron 1997;18:925-937
44. 2+ -independent α-latrotoxin-binding protein. J Biol Chem 1996;271:23239-23245
45. Chiba A, Kusunoki S, Obata H, et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745: 32-36
46. Benetar MG, Willison HJ, Vincent A. Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. J Neuroimmunol 1997;80:1-5